文献速递消化系统肿瘤

脂质体伊立替康联合5-氟尿嘧啶和亚叶酸钙治疗转移性胰腺癌患者的生活质量

Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
PubMed 文献 · Eur J Cancer · 2018-11-17

NAPOLI-1研究显示,脂质体伊立替康联合5-氟尿嘧啶和亚叶酸钙(nal-IRI+5-FU/LV)较5-FU/LV可延长既往吉西他滨治疗失败的转移性胰腺腺癌患者的总生存,且毒性可控。本文报告其健康相关生活质量(HRQOL)数据:在可评估患者中,除疲劳外,整体健康状况及功能/症状量表评分中位变化均≤10分;两组HRQOL改善或恶化的比例无显著差异。结论认为,nal-IRI+5-FU/LV在延长生存的同时维持了HRQOL。

要点

  • PRO人群共128例(nal-IRI+5-FU/LV组71例,5-FU/LV组57例),占意向治疗人群236例的54.2%。
  • 第6周和第12周时,整体健康状况及功能/症状量表评分中位变化大多≤10分。
  • 疲劳评分在nal-IRI+5-FU/LV组恶化11.1分,而5-FU/LV组无变化。

核心结论

  • 在NAPOLI-1研究中,对于既往接受过吉西他滨方案治疗的转移性胰腺腺癌患者,nal-IRI+5-FU/LV在显著延长生存的同时维持了健康相关生活质量。

研究设计与样本

  • NAPOLI-1研究(NCT01494506)的生活质量分析,患者在每个基线、每6周及研究治疗终止后30天完成EORTC QLQ-C30问卷。
  • 意向治疗人群共236例,PRO人群为完成基线及至少一次后续评估的128例(54.2%),其中nal-IRI+5-FU/LV组71例,5-FU/LV组57例。

主要发现

  • 第6周和第12周时,整体健康状况或功能及症状量表评分的中位变化≤10分,但疲劳例外:nal-IRI+5-FU/LV组恶化11.1分,5-FU/LV组无变化。
  • 两组HRQOL改善或恶化的患者比例无显著差异。
  • 未纳入PRO人群的108例(45.8%)患者中,大多数因疾病快速进展而难以参与评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The NAPOLI-1 study (NCT01494506) reported that liposomal irinotecan plus 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV) improved overall survival vs 5-FU/LV with manageable toxicity in patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based therapy. Yet, clinicians need treatment strategies that also maintain the patient's health-related quality of life (HRQOL). Here, we report the HRQOL data. METHODS: Patients completed the European Organisation for Research and Treatment of Cancer QOL core questionnaire C30 (EORTC QLQ-C30) at baseline, every 6 weeks, and at 30 days after discontinuation of study treatment. Patient-reported outcomes (PROs) were scored according to EORTC guidelines. nal-IRI+5-FU/LV HRQOL was compared with 5-FU/LV. The PRO population comprised intent-to-treat patients who completed baseline and at least one subsequent assessment on the EORTC QLQ-C30. Data were also analysed for missingness. RESULTS: Of 236 patients in the intent-to-treat population, 128 (54.2%) comprised the PRO population (71 in the nal-IRI+5-FU/LV arm; 57 the in 5-FU/LV arm). Of the remaining 108 patients (45.8%) not included in the PRO population, most progressed rapidly, making participation difficult. Median change from baseline was ≤10 points at weeks 6 and 12 in global health status or functional and symptom scale scores, except for fatigue, which deteriorated by 11.1 points with nal-IRI+5-FU/LV but did not change vs 5-FU/LV. The proportion of patients whose HRQOL improved or deteriorated was not significantly different between the arms. CONCLUSION: In the NAPOLI-1 study, HRQOL was maintained with nal-IRI+5-FU/LV in patients with metastatic pancreatic adenocarcinoma previously treated with a gemcitabine-based regimen, while survival was significantly extended.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hubner RA, Cubillo A, Blanc JF, et al. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. Eur J Cancer. 2018. PMID: 30458340. doi:10.1016/j.ejca.2018.09.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。